tranScrip occupies a unique place in the pharmaceutical service sector. Our expert teams help clients select the most promising drug candidates and bring them to the market applying our deep scientific knowledge combined with strategic, commercial and operational expertise.
We bring innovative solutions to clients’ global drug development needs. We deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory and commercial elements, from translational medicine through to registration and post licencing.
In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.
Our teams of physicians, scientists and regulatory experts work across a wide range of therapy areas. We lead and support many projects in oncology, immunology, infectious diseases and CNS, just to name a few. We have a lot of experience in advanced therapies and areas of high unmet medical need, including many orphan or rare diseases.
We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches.
We engage proactively with regulatory agencies and policymakers and drive innovative approaches to product development.
Integration with our clients
tranScrip’s key strength besides our in depth understanding of drug development is the ability to rapidly deploy multi-functional teams that provide strategic direction and operational support to a variety of projects, ranging from specific clinical or regulatory issues to coordinating large development programmes.
We are able to ramp up our teams during periods of intense activity and pull away when we are not needed, giving our clients maximum flexibility and avoiding unnecessary fixed costs.
We develop longstanding relationships with our pharma and biotech clients and bolt our teams into theirs seamlessly.
While tranScrip works for several of the top 50 pharma companies, many of the truly innovative early development projects come to us from small biotech’s, often operating virtually and requiring substantial support.